Leerink raised the firm’s price target on Novocure (NVCR) to $33 from $28 and keeps an Outperform rating on the shares after the company announced the Phase 3 PANOVA-3 study evaluating Tumor Treating Fields in unresectable, locally advanced pancreatic adenocarcinoma demonstrated a statistically significant median overall survival benefit. Based on the floor value of Optune in glioblastoma multiforme and the potential for revenue upside from additional TTFields indications in non-small cell lung cancer and PDAC, despite outstanding questions, the firm holds a “positive view” on Novocure relative to its current valuation, the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Morning Movers: Intel climbs following retirement of CEO Pat Gelsinger
- NovoCure’s TTFields Therapy Shows Promise in PANOVA-3 Trial
- Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
- Novocure announces PANOVA-3 trial met primary endpoint
- Novocure upgraded to Outperform from In Line at Evercore ISI